Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis
Cephalalgia · 2024
DOI: 10.1177/03331024241235156 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cephalalgia, 2024. Verfasst von Cristina Tassorelli und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy. Hauptthemen laut MEDLINE: Migraine Disorders, Piperidines, Pyridines, Pyrroles. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Background
Comparative evaluations of preventive migraine treatments can help inform clinical decision making for managing migraine in clinical practice.
Methods
An anchored matching-adjusted indirect comparison analysis was conducted using pooled participant-level data from two phase 3 atogepant trials (ADVANCE and PROGRESS) and one phase 2/3 rimegepant trial (BHV3000-305) to evaluate the relative efficacy and safety/tolerability of atogepant and rimegepant as preventive migraine treatments. Participants receiving atogepant 60 mg once daily, rimegepant orally disintegrating tablet 75 mg once every other day, and placebo were included. Only participants meeting the BHV3000-305 inclusion/exclusion criteria were analyzed: ≥6 monthly migraine days and ≤18 monthly headache days at baseline. The primary efficacy assessment of interest was change in monthly migraine days across weeks 1–12.
Results
There were 252 participants in the atogepant group and 348 in the rimegepant group. Across weeks 1–12, atogepant 60 mg demonstrated a significantly greater reduction in mean monthly migraine days compared with rimegepant 75 mg (mean difference [95% CI]: −1.65 [−2.49, −0.81]; p < 0.001). Both atogepant and rimegepant demonstrated similar safety/tolerability profiles.
Conclusion
In this matching-adjusted indirect comparison analysis, oral atogepant 60 mg once daily demonstrated a significantly greater reduction in monthly migraine days compared with rimegepant 75 mg orally disintegrating tablet once every other day.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
- Headache Science & Neurorehabilitation Centre, IRCCS C. Mondino Foundation and University of Pavia, Pavia, Italy.
- AbbVie, London, England.
- Mayo Clinic, Scottsdale, AZ, USA.
- AbbVie, North Chicago, IL, USA.
- AbbVie, Courbevoie, France.
ORCID-Profile: Cristina Tassorelli, Corey Voller
Förderung
- AbbVie
Zitieren
APA
Tassorelli, C., Onishchenko, K., Halker Singh, R. B., Duan, M., Dupont-Benjamin, L., Hemstock, M., Voller, C., McAllister, P., Nahas, S. J., Gandhi, P., & Ailani, J. (2024). Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis. Cephalalgia. https://doi.org/10.1177/03331024241235156
Vancouver
Tassorelli C, Onishchenko K, Halker Singh RB, Duan M, Dupont-Benjamin L, Hemstock M, et al. Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis. Cephalalgia. 2024. doi:10.1177/03331024241235156
BibTeX
@article{Tassorelli2024,
author = {Tassorelli, Cristina and Onishchenko, Kateryna and Halker Singh, Rashmi B and Duan, Molly and Dupont-Benjamin, Laure and Hemstock, Matthew and Voller, Corey and McAllister, Peter and Nahas, Stephanie J and Gandhi, Pranav and Ailani, Jessica},
title = {Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis},
journal = {Cephalalgia},
year = {2024},
doi = {10.1177/03331024241235156}
}
EUVIMED